title: Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT.
abstract: This study evaluated the safety and efficacy of thiotepa-based regimens before allogeneic stem cell transplantation in 310 adult patients with AML. Disease status at the time of transplantation was CR1 in 50%, CR2+ in 23.5% and advanced disease in 26.5%. Transplantation was performed from haploidentical (35%), matched sibling (27%), unrelated (20%) or cord blood (18%) donors. As for safety: mucositis occurred in 46.8% of the patients and the cumulative incidence (CI) of sinusoidal obstruction syndrome was 4.0%. With a median follow-up of 37 months, the CI of acute GvHD grade>II was 26.5%, whereas CI of chronic GvHD was 28.1% at 3 years. CI for non-relapse mortality at 3 years was 38.4%, 49.7% and 45.4% for patients in CR1, CR2+ and advanced disease, respectively (P=0.10). Relapse incidence at 3 years was 20.2, 30.7 and 40.6% in these three respective groups (P=0.002). CI for 3-year leukemia-free survival and overall survival were 41.4% and 45.6% (CR1), 19.6% and 27.7% (CR2+), and 13.9% and 13.6% (advanced disease), respectively (P<10-4for both). Our data suggest that thiotepa-based conditioning therapy in AML is feasible, effective and safe, as investigated for sinusoidal obstruction syndrome and mucositis.
authors.affiliation: EBMT Office Paris, Hôpital Saint-Antoine, Paris, France.|Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France.
authors.forename: S
authors.initials: S
authors.lastname: Eder
authors.affiliation: EBMT Office Paris, Hôpital Saint-Antoine, Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Labopin
authors.affiliation: Department of Medicine-Hematology, Oncology, University of Freiburg, Freiburg, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Finke
authors.affiliation: Klinik fuer Innere Medizin III, Universitätsklinikum Ulm, Ulm, Germany.
authors.forename: D
authors.initials: D
authors.lastname: Bunjes
authors.affiliation: Department of Hematology, Azienda Ospedali Riuniti di Ancona, Ancona-Torrete, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Olivieri
authors.affiliation: Department of Hematology, Ospedale Civile, Pescara, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Santarone
authors.affiliation: USC Ematologia, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.
authors.forename: A
authors.identifier: http://orcid.org/0000-0002-3739-7502
authors.initials: A
authors.lastname: Rambaldi
authors.affiliation: Abteilung II, Universität Tübingen, Tübingen, Germany.
authors.forename: L
authors.initials: L
authors.lastname: Kanz
authors.affiliation: Centro Trapianti Midollo Osseo, Azienda Ospedaliera 'BMM', Reggio Calabria, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Messina
authors.affiliation: EBMT Office Paris, Hôpital Saint-Antoine, Paris, France.|Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint-Antoine, Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Mohty
authors.affiliation: EBMT Office Paris, Hôpital Saint-Antoine, Paris, France.|Chaim Sheba Medical Center, Tel-Hashomer, Israel.
authors.forename: A
authors.initials: A
authors.lastname: Nagler
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D064591:Allografts; D018572:Disease-Free Survival; D005260:Female; D006086:Graft vs Host Disease / Q000401:mortality / Q000517:prevention & control; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D052016:Mucositis / Q000401:mortality / Q000517:prevention & control; D012008:Recurrence; D033581:Stem Cell Transplantation; D015996:Survival Rate; D013852:Thiotepa / Q000008:administration & dosage*; D019172:Transplantation Conditioning
chemical_list: D013852:Thiotepa